[1] |
NIE Yang, WANG Yue, WEI Jia.
Research progress on targeted therapy combined with immune-activating strategies in CLDN18.2-positive gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 146-158.
|
[2] |
CHEN Zhenmei, CHEN Jinhong.
Advances in precision diagnosis and treatment of cholangiocarcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 159-170.
|
[3] |
DU Nan, WEI Miaoyan, XU Jin.
Advancements and frontiers in targeted therapy for pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 183-192.
|
[4] |
BAI Haodong, SHA Bingxian, Ambedkar Kumar Yadav, XU Xianghuai, YU Li .
Targeted biotherapy for chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 377-382.
|
[5] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[6] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[7] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[8] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|
[9] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[10] |
WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan.
Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
|
[11] |
ZHOU Guangchen, LIU Yixi, ZHENG Yun.
Colorectal cancer and microRNA: research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
|
[12] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[13] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
[14] |
LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei.
Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
|
[15] |
LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian.
OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
|